Board of Directors

Philip Buchanan, PhD, FACMGG


Dr. Philip D. Buchanan, PhD., FACMGG is a Medical Geneticist and Clinical Cytogeneticist boarded by the American Board of Medical Genetics and Genomics and the American Board of Medical Specialists. He is an Adjunct Professor of Obstetrics and Gynecology at George Washington University. Dr. Buchanan graduated from North Carolina State University.

Post-doctoral studies were completed at the University of Michigan, Harvard University, and the University of Oregon. He joined the Department of Pediatrics at the University of North Carolina at Chapel Hill in 1970 to direct a new Prenatal Genetic Counseling Clinic and Cytogenetics Laboratory. Dr. Buchanan is a member of several professional societies. He presents and moderates at international meetings, publishes, teaches, and serves as a reviewer for peer-reviewed journals. He has served on college committees and as an NIH, FDA, NIEHS, and EPA Advisor. In 1983, Dr. Buchanan established GeneCare Medical Genetics Center in Chapel Hill. The Center had active international research, clinical laboratories, and teaching programs. Dr. Buchanan served as Executive Vice President for Genetics at Alere. He has helped start and manage multiple private and public companies and foundations. He served as Chairman of the Board for Vestrics, a predictive business analytics corporation. He currently serves as the Chairman of the Board for Voices Together. He serves on the board of the Fetal Medicine Foundation of the USA and of Biofluidica.

Rolf Muller, PhD


Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, product development, and successful product launches into global markets.

Before joining BioFluidica, he was the Founder and President of Biomatrica. He developed an idea to be a global leader in bio-preservation technologies for diagnostic and healthcare companies. Over the last 16 years, he has analyzed markets and developed strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.

Steven A. Soper, PhD


Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experience in the CTC research area along with being the author of five patents currently licensed by BioFluidica.

He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently the Foundation Distinguished Professor in Chemistry and Mechanical Engineering at Kansas University. He is also Director of the Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.

Michael Stocum


Michael is an entrepreneurial healthcare and life sciences professional with 20 years of experience leading innovative business initiatives across the pharmaceutical, biotechnology, and clinical laboratory industries by driving strategic vision, business partnerships, and value-added product development.

He has made significant impacts on the development and commercialization of over a dozen products in drug discovery & development, as well as several companion diagnostics, and contributed to the production of a biopharmaceutical. He is the Founder and President of Personalized Medicine Partners LLC. Prior he was the CEO of On-Q-ity and the Director of Business Development at GlaxoSmithKline.